02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
01:42 , Dec 13, 2018 |  BC Extra  |  Company News

Management tracks: Tamura reclaims CEO role at Sosei

Sosei Group Corp. (Tokyo:4565) said Peter Bains will step down as president and CEO and resign as director on Dec. 31. Executive Chairman, founder and former CEO Shinichi Tamura will replace Bains, effective Jan. 1....
22:35 , Sep 20, 2018 |  BC Extra  |  Company News

Management tracks: Garland to lead Portola; Gallagher joining Abingworth

Hematology company Portola Pharmaceuticals Inc. (NASDAQ:PTLA) hired Scott Garland as president and CEO. He replaces CEO Bill Lis, who retired Aug. 1. Interim Co-Presidents John Curnutte, the company’s head of R&D, and Mardi Dier, its...
23:48 , Sep 14, 2018 |  BioCentury  |  Finance

Solidifying Atreca’s repertoire

Atreca Inc. parlayed preclinical proof-of-concept data from its antibody platform into a $125 million series C round, which will enable the cancer immunotherapy company to bring its two lead programs into the clinic. An undisclosed,...
18:33 , Jun 29, 2018 |  BC Week In Review  |  Financial News

Tricida, Translate Bio, Forty Seven and Entera price IPOs

Among three well-funded biotechs that priced IPOs, Tricida Inc. (NASDAQ:TCDA) had by far the best first-day performance on June 28, posting a 37% gain, while Translate Bio Inc. (NASDAQ:TBIO) and Forty Seven Inc. (NASDAQ:FTSV) each...
05:15 , Jun 28, 2018 |  BC Extra  |  Financial News

Tricida gains, others dip after upsized IPOs

Among three well-funded biotechs that priced IPOs, Tricida Inc. (NASDAQ:TCDA) had by far the best first-day performance Thursday, posting a 37% gain, while Translate Bio Inc. (NASDAQ:TBIO) and Forty Seven Inc. (NASDAQ:FTSV) each lost ground....
13:47 , Jun 5, 2018 |  BC Extra  |  Financial News

Tricida files for $150M IPO

Renal disease company Tricida Inc. (South San Francisco, Calif.) filed to raise up to $150 million in an IPO on NASDAQ underwritten by Goldman Sachs, J.P. Morgan and Cowen. In 2H19, Tricida plans to submit...
21:20 , May 11, 2018 |  BC Extra  |  Company News

Management tracks: Synlogic, Akari

Synlogic Inc. (NASDAQ:SYBX) said President and CEO Jose Carlos Gutiérrez-Ramos has resigned. CMO Aoife Brennan will serve as interim president and CEO while the synthetic biology company seeks a successor. Autoimmune and inflammatory disease company...
06:12 , Jul 28, 2017 |  BC Week In Review  |  Clinical News

EC approves Vifor's Veltassa for hyperkalemia

Vifor Pharma Ltd. (SIX:VIFN) said the European Commission approved an MAA for Veltassa patiromer (RLY5016) to treat hyperkalemia in adults, including patients who develop the condition while undergoing renin-angiotensin-aldosterone system (RAAS) inhibitor therapy. Vifor said...
22:07 , Jul 21, 2017 |  BC Extra  |  Company News

EC approves Vifor's Veltassa for hyperkalemia

Vifor Pharma Ltd. (SIX:VIFN) said the European Commission approved Veltassa patiromer to treat hyperkalemia, including patients who develop the condition while undergoing renin-angiotensin-aldosterone system (RAAS) inhibitor therapy. Vifor said the application was also approved in...